-
公开(公告)号：US10590174B2
公开(公告)日：2020-03-17
申请号：US16311913
申请日：2017-07-07
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE LA REUNION SAINT DENIS , INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
Inventor： Gilles Gadea , Michael Girardot , Philippe Despres
IPC: C07K7/00 , C12N15/11 , A61K39/00 , C07K14/005 , C12N7/00
Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.
-
公开(公告)号：US20190255125A1
公开(公告)日：2019-08-22
申请号：US16307689
申请日：2017-06-22
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite de la Reunion Saint Denis , Institut de Recherche pour le Developpement (IRD) , Centre National de la Recherche Scientifique (CNRS)
Inventor： Philippe DESPRES , Gilles GADEA , Patrick MAVINGUI , Wildriss VIRANAICKEN
Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
-
公开(公告)号：US20190177373A1
公开(公告)日：2019-06-13
申请号：US16311913
申请日：2017-07-07
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE LA REUNION SAINT DENIS , INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT (IRD) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS
Inventor： Gilles GADEA , Michael GIRARDOT , Philippe DESPRES
IPC: C07K14/005 , C12N7/00
Abstract: The present invention relates to a genomic sequences encoding for an attenuated mutant Zika virus. The inventors have introduced some specific substitutions at very specific positions in the epidemic genomic sequence for restoring some fixation sites for miR-4279 that were originally present in the endemic genomic sequence. Moreover the inventors have additionally introduced mutation leading to the abrogation of the N-glycosylation site on the E protein which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular the present invention relates to a genomic sequence characterized by the sequence represented by SEQ ID NO:1 wherein at least one site of fixation for miR-4279 is restored.
-
Patent Agency Ranking
公开(公告)号：US20230302162A1
公开(公告)日：2023-09-28
申请号：US18061715
申请日：2022-12-05
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE LA REUNION
Inventor： Olivier MEILHAC , Emmanuelle JESTIN , Florian GUIBBAL , Sébastien BENARD
IPC: A61K51/04 , C07D239/95 , C07D403/06 , C07D405/12 , C07F5/02
CPC classification number: A61K51/0459 , C07D239/95 , C07D403/06 , C07D405/12 , C07F5/025 , A61K9/0019
Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
-
公开(公告)号：US10849943B2
公开(公告)日：2020-12-01
申请号：US16307689
申请日：2017-06-22
Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale) , Universite de la Reunion Saint Denis , Institut de Recherche pour le Developpement (IRD) , Centre National de la Recherche Scientifique (CNRS)
Inventor： Philippe Despres , Gilles Gadea , Patrick Mavingui , Wildriss Viranaicken
Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
-
6.发明公开公开(公告)号：US20240292837A1
公开(公告)日：2024-09-05
申请号：US18261799
申请日：2022-01-17
Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , CPE LYON , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT , UNIVERSITE CLAUDE BERNARD LYON 1 , UNIVERSITE DE LA REUNION , TROPICAL BIOCONTROL
Inventor： Mbolatiana Tovo ANDRIANJAFY , Voahangy VESTALYS , Marc LEMAIRE , Patrick MAVINGUI , Fenia Diane RAMIHARIMANANA , Saholy LAMARE
Abstract: Disclosed is the use of a compound with the following formula (I):
R is a linear or branched alkyl group including from 2 to 20 carbon atoms, the compound being in the form of a racemic mixture, an enantiomer (R) or an enantiomer (S), as an attractant or repellent for blood-sucking, biting invertebrates.-
公开(公告)号：US11583596B2
公开(公告)日：2023-02-21
申请号：US16650532
申请日：2018-09-26
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE LA REUNION
Inventor： Olivier Meilhac , Emmanuelle Jestin , Florian Guibbal , Sébastien Benard
IPC: A61K49/04 , A61K51/04 , C07D239/95 , C07D403/06 , C07D405/12 , C07F5/02 , A61K9/00
Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
-
公开(公告)号：US20200276337A1
公开(公告)日：2020-09-03
申请号：US16650532
申请日：2018-09-26
Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE DE LA REUNION
Inventor： Olivier MEILHAC , Emmanuelle JESTIN , Florian GUIBBAL , Sébastien BENARD
IPC: A61K51/04 , C07D239/95 , C07F5/02 , C07D405/12 , C07D403/06
Abstract: The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.012 seconds)
